strategies-to-reduce-bispecific-antibody-viscosity
Are you a CMC or Drug Product leader grappling with complex biologic challenges? High viscosity, particularly in bispecific antibodies, can significantly hinder development. Explore expert strategies to streamline your formulation and get your drug ready for market.
Menu
Getting Your Drug Ready: A Guide for CMC and Drug Product Leaders
What's Happening Now
Common Market Trends
What's Hard Now and How We're Fixing It
How Leukocare Can Help with These Problems
What Our Customers Get
FAQ
Getting Your Drug Ready: A Guide for CMC and Drug Product Leaders
Getting a promising molecule all the way to a drug ready for market is complex. If you're a leader in Chemistry, Manufacturing, and Controls (CMC) or Drug Product Development, you know this journey well – it's full of scientific challenges and big decisions. This article discusses what's happening in drug development, the trends, the challenges, and how working together on formulation can really make a difference.
What's Happening Now
We're seeing more and more complex biologics coming through the biopharmaceutical pipeline. [1] Monoclonal antibodies, cell and gene therapies, and other advanced therapeutic medicinal products (ATMPs) are becoming more common. [11, 2] These molecules are different from typical small-molecule drugs, and they come with their own unique stability and manufacturing hurdles. [4] Because they're big and complex, they're super sensitive to their surroundings, making formulation a trickier job. [4]
Everyone's always pushing to speed up development. If a product is on the fast track, getting to a Biologics License Application (BLA) quickly is the main goal. Small biotech companies, often with good funding and focusing on one molecule, need to get their cell line, process, and formulation just right all at the same time. Even big pharma companies are exploring new areas like viral vectors and RNA, even if they don't have much in-house experience.
Common Market Trends
A few things are really changing how we develop drugs:
Everyone outsources now: Lots of biotech companies, especially the smaller ones, get everything done by outside partners. [6, 7] They rely on a network of contract development and manufacturing organizations (CDMOs) for everything from cell line development to fill-finish. [8] They do this because they need special skills and it's super expensive to build and keep up their own manufacturing facilities. [9]
Biologics are booming: The market for biologic drugs is really taking off. [10] That means there's a bigger need for special ways to formulate and deliver these drugs. [10]
New drug types are a big focus: There's a big push into new therapies like viral vectors, RNA-based medicines, and antibody-drug conjugates (ADCs). [11, 2] These new drug types come with new formulation problems. [12, 13]
AI's role in formulation: Artificial intelligence (AI) and machine learning (ML) are becoming key tools to make drug formulation better. [14, 15, 16] They can help predict how stable a drug will be, check out different ingredients, and speed up development.
Designing for patients first: People are really focusing on making drugs easier for patients to use, like shots they can give themselves under the skin. [18] This means thinking carefully about things like how thick the liquid is and how much needs to be injected. [18]
What's Hard Now and How We're Fixing It
Getting a drug product that works and stays stable isn't easy. Here are some common problems and how we're dealing with them:
Biologics don't always stay stable: Big molecules can clump together, break down, or lose their effectiveness. [4] Picking the right buffers, ingredients, and storage conditions is super important to keep them stable. [4, 20] Freeze-drying (lyophilization) is often used to make biologics stable for longer. [10]
Formulating for high concentrations: Lots of biologic drugs need to be given in high doses, especially for shots under the skin. [21] This can cause problems with how thick the liquid is and proteins clumping up. [18] Scientists are looking into new ingredients and methods to get around these issues. [18]
New drug types, new problems: Making new therapies like viral vectors and RNA-based medicines needs a whole new way of thinking. These molecules need special stability care and can be tough to produce in large amounts. Getting them to the right parts of the body is another huge hurdle. [13, 23]
CMC causes delays: Problems with Chemistry, Manufacturing, and Controls (CMC) often hold up clinical trials. [24] The FDA is looking really closely at manufacturing and quality controls. [24] Planning CMC thoroughly and early on is key to avoiding these problems. [24]
Picking the right partner: Since everyone's outsourcing more, choosing the right CDMO is a big deal. [8] A good partner doesn't just offer space; they bring technical know-how and a willingness to work together. [25]
To handle these problems, companies are taking a more thought-out and team-based approach to formulation. This includes:
Early formulation check: Getting formulation development started early can help spot problems and make the project less risky.
Using standard formulation tools: Sticking with proven formulation methods can simplify development and speed things up.
Decisions based on data: Using analysis tools and prediction models helps you make smart choices about what goes into your formulation and how to process it.
Solid partnerships: Building strong, collaborative relationships with CDMOs and other service providers is super important for success. [25]
How Leukocare Can Help with These Problems
Leukocare has a special way of doing formulation development that solves the main headaches for biotech and pharma companies. By mixing our own special formulation tech with AI-powered prediction models, we help our partners get through the tough parts of drug product development.
For the Fast-Track Biotech Leader, we aim to give you a quick, clear path to BLA. We get the pressure to deliver and the need for a formulation that's good for regulators and ready for the market. Our Smart Formulation Platform and AI-supported stability prediction let us design formulations based on data, perfect for tight schedules. We act like a strategic co-pilot, working closely with experienced CMC pros.
For the Small Biotech that knows CMC, we give you structure, speed, and real value. We know you're busy and need a reliable partner who can jump in and help with quick development. Our clear talks, proactive way of working, and structured processes mean a smooth journey to IND/Ph I.
For Mid-size Biotechs, we help you 'break in' and tackle specific problems. When your current vendors are swamped or new drug types throw unexpected curveballs, we can step in and solve tough issues. We offer a 'try it out' approach, showing what we can do on a small scale before you go big.
For Pharma companies exploring a New Modality, we bring deep technical knowledge and a true partnership. We give specific insights, case studies, and custom support materials to help your internal teams learn and make smart, regulatory-friendly decisions.
For CDMOs looking for a Network Partner, we act as a quiet, smooth, and science-backed formulation team. We get that you need a discreet, easy-to-work-with partner who can give you data-driven formulation answers without any hassle. We're loyal to our CDMO partners, and our practical approach ensures external formulation projects run smoothly.
What Our Customers Get
The main thing we offer is making drug development less risky and faster. Our clients get:
Smart formulation based on data: Our prediction models and custom experiments (DoEs) give you a solid scientific basis for your formulation choices.
Expert help you can trust: We have a team of experienced pros who can give you reliable, data-driven advice for when you're swamped or have tricky, unique problems.
A true partner: We're not just a service provider; we're a strategic partner who cares about your project's success.
Custom solutions: We don't just use templates. We give you real data, real expertise, and custom formulation designs to guide your drug's journey.
Smooth teamwork: We fit right in with your team, acting as a quiet, smooth, and science-backed extension of what you can do.
By solving the specific problems each type of client faces, we help them confidently tackle drug formulation.
FAQ
What's the difference between formulating a biologic and a small molecule drug?
Biologics are way bigger and more complex than small molecules, which makes them super sensitive to their surroundings. Their formulation requires careful control of factors like pH, temperature, and ionic strength to prevent degradation and maintain activity. [4]
Why is CMC such a big deal in drug development?
CMC covers everything about how a drug is made and checked to ensure it's top quality, safe, and consistent. Regulatory groups need detailed CMC paperwork to approve clinical trials and get drugs to market. [24] If there are any issues with CMC, things can get seriously delayed. [24]
What does a CDMO do?
A Contract Development and Manufacturing Organization (CDMO) offers outsourced services to pharma and biotech companies, like drug development, manufacturing, and formulation. [8]
How are they using AI in drug formulation?
AI and machine learning are used to crunch huge amounts of data, guess how stable different formulations will be, and pick the best ingredients. [14, 16] This can really speed up development and boost the chances of successful formulation. [15]
What are the big challenges in making new drug types like viral vectors and RNA?
These new therapies come with their own unique stability and delivery problems. For instance, RNA is known for being unstable, and it can be hard to make large amounts of viral vectors. Delivering these therapies to the right cells in the body is another huge obstacle. [13, 23]
